Plain-English translation of NCT05665738 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing high-dose rate brachytherapy (HDR brachytherapy) as a faster treatment option for men with early-stage prostate cancer. Instead of receiving radiation therapy over several days or weeks, this treatment delivers the full dose in two sessions just three hours apart, all in a single day. The goal is to see if this compressed schedule is safe and effective.
Standard prostate cancer radiation treatment often requires multiple visits over weeks or months. This trial exists to see whether delivering the same radiation dose more quickly—in just one day—works just as well while being more convenient for patients and reducing the overall time spent in treatment.
You likely qualify if…
You likely don't qualify if…
You would come to the hospital or clinic for one full day of treatment. You'll receive general anesthesia, and the radiation therapy will be delivered in two sessions separated by three hours, both completed on that same day. After treatment, you'll go home and return for follow-up visits: every three months for the first year, then every four months in year two, every six months in years three through five, and annually after that. During these visits, your doctors will check your recovery and measure your PSA levels to ensure the treatment is working.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
United States